isradipine has been researched along with Body Weight in 19 studies
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A short-term trial of isradipine was conducted to assess its effectiveness and tolerability in the treatment of mild-to-moderate hypertension." | 9.07 | Isradipine in the treatment of mild-to-moderate hypertension in Portugal. ( Correa-Nunes, A; Mariano-Pego, G; Pereira-Miguel, JM; Rocha-Gonçalves, F, 1992) |
| "Isradipine is an effective, orally administered agent for control of hypertension in children." | 7.70 | Initial experience with isradipine for the treatment of hypertension in children. ( Groshong, T; Strauser, LM; Tobias, JD, 2000) |
| "A short-term trial of isradipine was conducted to assess its effectiveness and tolerability in the treatment of mild-to-moderate hypertension." | 5.07 | Isradipine in the treatment of mild-to-moderate hypertension in Portugal. ( Correa-Nunes, A; Mariano-Pego, G; Pereira-Miguel, JM; Rocha-Gonçalves, F, 1992) |
| "Isradipine, a new antihypertensive dihydropyridine calcium antagonist, was evaluated for its efficacy, tolerability, and safety in 91 ambulatory patients who had mild-to-moderate hypertension." | 5.07 | Multicenter evaluation of efficacy, tolerability and safety of a new first-line antihypertensive drug, isradipine, in a Latin-American population. ( Acevedo, L; Gamarra, G; Gómez, G; Izurieta, A; Melgarejo, E; Narváez, J; Restrepo, G, 1991) |
| "Seventeen middle-aged males with sustained essential hypertension (WHO stage II) and diastolic blood pressures (BP) exceeding 100 mm Hg during a placebo run-in period completed a trial to assess the hemodynamic effects of isradipine, a new dihydropyridine calcium antagonist." | 5.06 | Central hemodynamics and brachial artery compliance during therapy with isradipine, a new calcium antagonist. ( Andersson, OK; Persson, B; Widgren, BR; Wysocki, M, 1990) |
| "Twenty-three middle-aged men (59 +/- 2 years) with sustained, essential hypertension (WHO Stage II) and with diastolic blood pressure exceeding 100 mmHg during a run-in placebo month were included in a trial designed to assess the clinical and haemodynamic effects of isradipine, a novel dihydropyridine calcium antagonist." | 5.06 | Blood pressure control and haemodynamic adaptation with the dihydropyridine calcium antagonist isradipine: a controlled study in middle-aged hypertensive men. ( Andersson, OK; Aurell, M; Hedner, T; Persson, B; Wysocki, M, 1989) |
| "The long-term efficacy of isradipine, a new dihydropyridine calcium antagonist with marked vascular selectivity, was evaluated in 17 patients with essential hypertension." | 5.06 | The long-term effect of isradipine in pindolol-treated patients. ( Andrén, L; Dahlöf, B; Eggertsen, R; Hansson, L; Jern, S; Svensson, A, 1987) |
| "Isradipine is an effective, orally administered agent for control of hypertension in children." | 3.70 | Initial experience with isradipine for the treatment of hypertension in children. ( Groshong, T; Strauser, LM; Tobias, JD, 2000) |
| "The effect of regression of left ventricular hypertrophy was studied in deoxycorticosterone-acetate-salt hypertensive rats (DOCA-salt hypertensive rats) treated with tetrandrine." | 3.69 | Effects of tetrandrine on left ventricle hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. ( Rao, MR; Xu, Y, 1995) |
| "To examine the status of ATP-sensitive K+ (K+ATP) channels and 1,4-dihydropyridine-sensitive Ca2+ (Ca2+DHP) channels during experimental cardiac failure, we have measured the radioligand binding properties of [3H]glyburide and [3H]PN 200 110, respectively, in tissue homogenates from the rat cardiac left ventricle, right ventricle, and brain 4 wk after myocardial infarction induced by left coronary artery ligation." | 3.68 | Regulation of K+ and Ca2+ channels in experimental cardiac failure. ( Bauer, JA; Fung, HL; Gopalakrishnan, M; Kwon, YW; Rutledge, A; Triggle, DJ, 1991) |
| "Drug level monitoring during routine clinical visits in the course of phase III trials provides a means to document pharmacokinetic variability in a patient population." | 2.67 | Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine. ( Fertil, B; Jais, JP; Laplanche, R; Niederberger, W; Nüesch, E; Steimer, JL, 1991) |
| "Treatment with isradipine alone caused a sustained reduction in blood pressure (-22/-10 mm Hg, P < 0." | 1.29 | Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment. ( Berne, C; Lind, L; Lithell, H; Pollare, T, 1994) |
| "Isradipine treatment had no effect on vasoconstrictor responses to norepinephrine in vitro." | 1.28 | Effect of chronic treatment with the calcium entry blocker, isradipine, on vascular calcium overload produced by vitamin D3 and nicotine in rats. ( Atkinson, J; Capdeville-Atkinson, C; Chillon, JM; Henrion, D, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 14 (73.68) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clark, NC | 1 |
| Nagano, N | 1 |
| Kuenzi, FM | 1 |
| Jarolimek, W | 1 |
| Huber, I | 1 |
| Walter, D | 1 |
| Wietzorrek, G | 1 |
| Boyce, S | 1 |
| Kullmann, DM | 1 |
| Striessnig, J | 1 |
| Seabrook, GR | 1 |
| Xu, Y | 1 |
| Rao, MR | 1 |
| Lind, L | 1 |
| Berne, C | 1 |
| Pollare, T | 1 |
| Lithell, H | 1 |
| Yoshida, M | 2 |
| Latifpour, J | 2 |
| Weiss, RM | 2 |
| Gardell, LR | 2 |
| Reid, LD | 2 |
| Boedeker, KL | 2 |
| Liakos, TM | 1 |
| Hubbell, CL | 2 |
| Cramer, CM | 1 |
| Harris, JR | 1 |
| Strauser, LM | 1 |
| Groshong, T | 1 |
| Tobias, JD | 1 |
| Henrion, D | 1 |
| Chillon, JM | 1 |
| Capdeville-Atkinson, C | 1 |
| Atkinson, J | 1 |
| Pereira-Miguel, JM | 1 |
| Correa-Nunes, A | 1 |
| Rocha-Gonçalves, F | 1 |
| Mariano-Pego, G | 1 |
| Hof, RP | 1 |
| Umemura, K | 1 |
| Evenou, JP | 1 |
| Hof, A | 1 |
| Rüegg, PC | 1 |
| Galletti, F | 1 |
| Rutledge, A | 2 |
| Krogh, V | 1 |
| Triggle, DJ | 2 |
| Gopalakrishnan, M | 1 |
| Kwon, YW | 1 |
| Bauer, JA | 1 |
| Fung, HL | 1 |
| Andersson, OK | 2 |
| Persson, B | 2 |
| Widgren, BR | 1 |
| Wysocki, M | 2 |
| Gómez, G | 1 |
| Melgarejo, E | 1 |
| Narváez, J | 1 |
| Gamarra, G | 1 |
| Restrepo, G | 1 |
| Acevedo, L | 1 |
| Izurieta, A | 1 |
| Laplanche, R | 1 |
| Fertil, B | 1 |
| Nüesch, E | 1 |
| Jais, JP | 1 |
| Niederberger, W | 1 |
| Steimer, JL | 1 |
| Dillon, JS | 1 |
| Gu, XH | 1 |
| Nayler, WG | 1 |
| Hedner, T | 1 |
| Aurell, M | 1 |
| Dahlöf, B | 1 |
| Andrén, L | 1 |
| Eggertsen, R | 1 |
| Jern, S | 1 |
| Svensson, A | 1 |
| Hansson, L | 1 |
6 trials available for isradipine and Body Weight
| Article | Year |
|---|---|
Isradipine in the treatment of mild-to-moderate hypertension in Portugal.
Topics: Adolescent; Adult; Aged; Blood Pressure; Body Weight; Calcium Channel Blockers; Dihydropyridines; Fe | 1992 |
Central hemodynamics and brachial artery compliance during therapy with isradipine, a new calcium antagonist.
Topics: Ankle; Blood Pressure; Body Weight; Brachial Artery; Calcium Channel Blockers; Double-Blind Method; | 1990 |
Multicenter evaluation of efficacy, tolerability and safety of a new first-line antihypertensive drug, isradipine, in a Latin-American population.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Cohort Studies; Colombia; Dose-Re | 1991 |
Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine.
Topics: Adult; Aged; Aging; Analysis of Variance; Biological Availability; Body Height; Body Weight; Calcium | 1991 |
Blood pressure control and haemodynamic adaptation with the dihydropyridine calcium antagonist isradipine: a controlled study in middle-aged hypertensive men.
Topics: Administration, Oral; Ankle; Blood Pressure; Body Weight; Calcium Channel Blockers; Clinical Trials | 1989 |
The long-term effect of isradipine in pindolol-treated patients.
Topics: Aged; Body Weight; Calcium Channel Blockers; Double-Blind Method; Drug Therapy, Combination; Edema; | 1987 |
13 other studies available for isradipine and Body Weight
| Article | Year |
|---|---|
Neurological phenotype and synaptic function in mice lacking the CaV1.3 alpha subunit of neuronal L-type voltage-dependent Ca2+ channels.
Topics: Animals; Behavior, Animal; Binding Sites; Body Weight; Calcium Channel Blockers; Calcium Channels; C | 2003 |
Effects of tetrandrine on left ventricle hypertrophy in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Alkaloids; Animals; Antihypertensive Agents; Benzylisoquinolines; Binding, Competitive; Blood Pressu | 1995 |
Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment.
Topics: Adult; Blood Glucose; Blood Pressure; Body Weight; Drug Therapy, Combination; Female; Hemoglobin A; | 1994 |
Age-related changes in Ca2+ channel antagonist receptors in rabbit lower urinary tract.
Topics: Aging; Animals; Animals, Newborn; Body Weight; Calcium Channel Agonists; Calcium Channels; Female; I | 1993 |
Isradipine and naltrexone in combination with isradipine interact with a period of abstinence to reduce rats' intakes of an alcoholic beverage.
Topics: Alcohol Drinking; Alcoholic Beverages; Animals; Behavior, Animal; Body Weight; Dose-Response Relatio | 1997 |
Isradipine combined with naltrexone persistently reduces the reward-relevant effects of cocaine and alcohol.
Topics: Animals; Body Weight; Calcium Channel Blockers; Central Nervous System Depressants; Cocaine; Conditi | 1998 |
Initial experience with isradipine for the treatment of hypertension in children.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Body Weight; Calcium Channel Blockers | 2000 |
Effect of chronic treatment with the calcium entry blocker, isradipine, on vascular calcium overload produced by vitamin D3 and nicotine in rats.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Body Weight; Calcium; Calcium Channel Blockers; Cholecalci | 1992 |
Effects of isradipine on plasma renin activity in sodium-loaded and -depleted conscious rabbits.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Calcium Channel | 1992 |
Age-related changes in calcium antagonist receptors in rabbit ureter.
Topics: Aging; Animals; Binding Sites; Body Weight; Calcium Channel Blockers; Female; Isradipine; Muscle, Sm | 1992 |
Age related changes in Ca2+ channels in spontaneously hypertensive rats.
Topics: Aging; Animals; Body Weight; Brain; Calcium Channel Blockers; Calcium Channels; In Vitro Techniques; | 1991 |
Regulation of K+ and Ca2+ channels in experimental cardiac failure.
Topics: Animals; Body Weight; Brain; Calcium Channel Blockers; Calcium Channels; Coronary Vessels; Dihydropy | 1991 |
Effect of age and of hypertrophy on cardiac Ca2+ antagonist binding sites.
Topics: Aging; Animals; Blood Pressure; Body Weight; Calcium Channels; Cardiomegaly; Cell Membrane; Dihydrop | 1989 |